NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free OTLK Stock Alerts $8.77 +0.34 (+4.03%) (As of 11:57 AM ET) Add Compare Share Share Today's Range$8.35▼$8.9450-Day Range$5.73▼$11.9452-Week Range$4.00▼$40.60Volume51,871 shsAverage Volume519,528 shsMarket Capitalization$114.10 millionP/E RatioN/ADividend YieldN/APrice Target$46.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Outlook Therapeutics alerts: Email Address Outlook Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside439.8% Upside$46.43 Price TargetShort InterestHealthy7.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 11 Articles This WeekInsider TradingAcquiring Shares$22,245 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.99) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.87 out of 5 starsMedical Sector430th out of 915 stocksBiological Products, Except Diagnostic Industry67th out of 155 stocks 3.4 Analyst's Opinion Consensus RatingOutlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOutlook Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.41% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Outlook Therapeutics has recently decreased by 15.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OTLK. Previous Next 3.0 News and Social Media Coverage News SentimentOutlook Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Outlook Therapeutics this week, compared to 3 articles on an average week.Search Interest65 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,245.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($2.99) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Outlook Therapeutics Stock (NASDAQ:OTLK)Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More OTLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLK Stock News HeadlinesMarch 30, 2024 | insidertrades.comYezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) StockApril 29, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseApril 29, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 29, 2024 | msn.comThese 5 programs are way better than Microsoft OutlookApril 29, 2024 | usnews.comHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 OutlookApril 29, 2024 | americanbankingnews.comShort Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Declines By 15.0%April 29, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation CouncilApril 26, 2024 | finance.yahoo.comGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036April 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 26, 2024 | msn.comHow to Use Copilot in OutlookApril 22, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to PositiveApril 22, 2024 | markets.businessinsider.comWGA Releases New Housing Finance OutlookApril 22, 2024 | msn.comOutlook: How to set up breaks between your meetingsApril 21, 2024 | finance.yahoo.comOutlook Therapeutics, Inc. (OTLK)April 18, 2024 | finance.yahoo.comWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and PricesApril 18, 2024 | usnews.comBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024April 15, 2024 | globenewswire.comOutlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 14, 2024 | msn.comMicrosoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?April 14, 2024 | msn.comUS Consumer Sentiment Falls Slightly as Outlook for Inflation WorsensApril 11, 2024 | fxstreet.comFed's Williams: Outlook is uncertain, Fed must be data-dependentApril 11, 2024 | msn.comStock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate CutApril 11, 2024 | msn.comBitdefender now has identity protection for Gmail and OutlookApril 10, 2024 | finance.yahoo.comInsiders are Piling into These 10 Healthcare Stocks in 2024April 3, 2024 | forbes.comUsers Complain Gmail Blocks Email From Microsoft Outlook—Here’s The FixApril 3, 2024 | msn.comOutlook.com trips over Google's spam blocking rulesMarch 29, 2024 | uk.investing.comBTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 successSee More Headlines Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$46.43 High Stock Price Target$100.00 Low Stock Price Target$20.00 Potential Upside/Downside+450.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,741.39% Return on Assets-132.37% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-7.59Miscellaneous Outstanding Shares13,010,000Free Float12,323,000Market Cap$109.67 million OptionableOptionable Beta0.04 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Ralph H. Thurman (Age 75)Independent Executive Chairman Comp: $207.5kMr. C. Russell Trenary III (Age 66)President, CEO & Director Comp: $610.9kMr. Lawrence A. Kenyon CPA (Age 58)Executive VP, CFO, Treasurer, Company Secretary & Director Mr. Jeffrey Evanson (Age 55)Chief Commercial Officer Comp: $451.17kMs. Alicia TozierSenior Vice President, Marketing & Market AccessMr. Joel PrieveSenior Vice President of Licensing and M&ADr. Surendra Sharma M.D.Senior Vice President of Medical AffairsDr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory AffairsMr. Jedd ComiskeySenior VP - Head of EuropeMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEBioAtlaNASDAQ:BCABaTyr PharmaNASDAQ:LIFEVigil NeuroscienceNASDAQ:VIGLSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Bought 311,775 shares on 4/25/2024Ownership: 2.396%Yezan Munther HaddadinBought 1,882 shares on 3/28/2024Total: $22,245.24 ($11.82/share)Scotia Capital Inc.Sold 54,359 shares on 2/12/2024Ownership: 0.109%View All Insider TransactionsView All Institutional Transactions OTLK Stock Analysis - Frequently Asked Questions Should I buy or sell Outlook Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OTLK shares. View OTLK analyst ratings or view top-rated stocks. What is Outlook Therapeutics' stock price target for 2024? 8 Wall Street analysts have issued 1-year price targets for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they anticipate the company's stock price to reach $46.43 in the next twelve months. This suggests a possible upside of 439.8% from the stock's current price. View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts. How have OTLK shares performed in 2024? Outlook Therapeutics' stock was trading at $7.88 at the start of the year. Since then, OTLK shares have increased by 9.1% and is now trading at $8.60. View the best growth stocks for 2024 here. Are investors shorting Outlook Therapeutics? Outlook Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,130,000 shares, a decline of 15.0% from the March 31st total of 1,330,000 shares. Based on an average daily volume of 639,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 7.4% of the company's stock are short sold. View Outlook Therapeutics' Short Interest. When is Outlook Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our OTLK earnings forecast. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) released its earnings results on Wednesday, February, 14th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.20. When did Outlook Therapeutics' stock split? Outlook Therapeutics's stock reverse split on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX). Who are Outlook Therapeutics' major shareholders? Outlook Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (2.40%). Insiders that own company stock include C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Terry Dagnon and Yezan Munther Haddadin. View institutional ownership trends. How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OTLK) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsTrump is sounding the alarmPreserve GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.